AU - Vaitheeshvaran, Selvarasu AU - Hedina, Manickam TI - Remarkable achievements in multiple sclerosis PT - REVI DP - 2016 Apr 1 TA - Clinical Trials in Degenerative Diseases PG - 77-83 VI - 1 IP - 2 4099- https://www.clinicaltdd.com/article.asp?issn=2542-3975;year=2016;volume=1;issue=2;spage=77;epage=83;aulast=Vaitheeshvaran;type=0 4100- https://www.clinicaltdd.com/article.asp?issn=2542-3975;year=2016;volume=1;issue=2;spage=77;epage=83;aulast=Vaitheeshvaran AB - Multiple sclerosis as a demyelinating disease is characterized by divergent clinical symptoms in the central nervous system. To date, its etiology is still indefinite. Out of the human leukocyte antigen (HLA) region, there are different aspects contributing to multiple sclerosis. Some genome-wide association studies have shown several non-HLA genes play a major role in multiple sclerosis. Additionally, a few single nucleotide polymorphisms in non-HLA genes are likely to be predisposing markers for multiple sclerosis, including rs6897932 in IL7RA, and rs2104286, rs12044852 in IL2RA and CD58 genes, respectively. However, the exact region in the mitochondria is still now indefinite. Given that relevant studies are mostly from Europe, further investigation in different cohorts throughout the world is warranted.